Who is sponsoring NCT05967884?

NCT05967884 is sponsored by Ottawa Hospital Research Institute.

What drugs are being tested in NCT05967884?

Interventions in NCT05967884: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab.

What condition does NCT05967884 study?

NCT05967884 studies Breast Cancer.

Is NCT05967884 still recruiting?

NCT05967884 is currently status unknown. Last updated 1 August 2023.

Last reviewed 2023-08-01 · How we verify

NCT05967884

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Status unknown Phase 2 Last updated 1 August 2023

What this trial tests

Phase 2 trial testing Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab in Breast Cancer in 20 participants. Status unknown.

Timeline

4 August 2023

Primary endpoint
1 August 2024

1 August 2024

Quick facts

Lead sponsor	Ottawa Hospital Research Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	4 August 2023
Primary completion	1 August 2024
Estimated completion	1 August 2024
Sites	2 locations across Canada

Drugs / interventions tested

Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Ottawa Hospital Research Institute

Who can join

Adults 18 to 90, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor positive (ER+) breast cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation in cancer: therapeutic opportunities from new insights.
Xie Y, Liu F, Wu Y, Zhu Y, et al · · 2025 · cited 53× · PMID 39994787 · DOI 10.1186/s12943-025-02243-8
Tumor secretome shapes the immune landscape during cancer progression.
Yang J, Tang S, Saba NF, Shay C, et al · · 2025 · cited 16× · PMID 39930476 · DOI 10.1186/s13046-025-03302-0
JAK/STAT-mediated regulation of PD-L1 expression in breast cancer: Molecular mechanisms and implications for immunotherapy.
Sang H, Zhao X. · · 2026 · PMID 41858895 · DOI 10.1016/j.isci.2026.114826

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Ottawa Hospital Research Institute trials

Trials by the same sponsor.

NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05967884 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
Last refreshed: 1 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05967884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing